## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.21 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Consistent execution (4/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($115.66)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. GILD: Wells Fargo Raises Price Target for Gilead Sciences | GILD Stock News**
- Source: GuruFocus | 20251210T204925 | Bullish | Relevance: 99%
-  Wells Fargo analyst Mohit Bansal has increased the price target for Gilead Sciences (GILD) to $150.00 from $145.00, maintaining an "Overweight" rating due to optimistic expectations for the company's performance. Despite this, GuruFocus estimates a downside of 23.99% for GILD's fair value. The article also provides a summary of recent analyst ratings and the company's focus on therapies for infectious diseases and oncology.

**2. Investment Management Corp of Ontario Trims Stock Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251209T150817 | Somewhat-Bullish | Relevance: 99%
-  Investment Management Corp of Ontario (IMCO) reduced its stake in Gilead Sciences (NASDAQ:GILD) by 11.1% in Q2 2025, selling 22,806 shares and ending with 181,827 shares valued at $20.159 million. Despite this, institutional ownership of Gilead remains high at 83.67%, with other major firms like Norges Bank, Price T Rowe, Invesco, and Vanguard increasing their positions. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $130.65, with some recent price target increases into the $135â€“$145 range.

**3. Gilead Sciences, Inc. $GILD Shares Bought by Natixis**
- Source: MarketBeat | 20251208T130820 | Bullish | Relevance: 99%
- Natixis significantly increased its stake in Gilead Sciences (NASDAQ:GILD) by 44.3% in Q2, acquiring an additional 116,861 shares, bringing its total holdings to 380,753 shares valued at approximately $42.2 million. This comes as Gilead reported strong Q3 earnings, beating analyst estimates with $2.47 EPS and $7.77 billion in revenue, and declared a quarterly dividend of $0.79 per share. Despite insider sales, analysts maintain a "Moderate Buy" consensus rating for Gilead, with a target price of $130.65.

**4. Gilead Sciences (NASDAQ:GILD) Price Target Raised to $133.00 at HSBC**
- Source: MarketBeat | 20251210T145819 | Bullish | Relevance: 98%
- HSBC has increased its price target for Gilead Sciences (NASDAQ:GILD) to $133.00 from $110.00, maintaining a "hold" rating, indicating a potential upside of 11.81%. Other analysts have also issued positive ratings, contributing to an average "Moderate Buy" rating and an average price target of $130.96 for the biopharmaceutical company. Gilead Sciences recently reported strong Q3 earnings, exceeding analyst expectations, and provided its FY 2025 guidance.

**5. Cantor Fitzgerald Maintains a Buy Rating on Gilead Sciences (GILD)**
- Source: Insider Monkey | 20251210T112800 | Bullish | Relevance: 98%
-  Cantor Fitzgerald analyst Carter Gould reiterated a Buy rating and a $135 price target for Gilead Sciences (NASDAQ: GILD) on December 7, 2025. This follows new data from Kite, a Gilead company, demonstrating consistent benefits of second-line Yescarta therapy for patients with relapsed/refractory large B-cell lymphoma. The company is recognized for its biopharmaceutical advancements in serious diseases like cancer and HIV.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-10 | Wells Fargo | $150 | $145 | +3% |
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Insider selling cluster: $7.1M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 13.9x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.6B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 13.9 |
| Current P/E | 14.9 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -3.6% to -4.9% (-1.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.9pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.87), momentum weakening. RSI neutral at 46.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.92% (CS: 17) | Weak |
| RSI_14 | 46.2 | Neutral |
| MACD Histogram | -0.87 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.073x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $121.34
- **Stop Loss:** $115.66 (4.7% risk)
- **Target:** $132.70 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $10,677.92
- **Portfolio %:** 10.68%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*